Catalyst Pharmaceuticals Receives Prestigious Ranking on Forbes 2026 List of America's Most Successful Small-Cap Companies
CPRXCORAL GABLES, Fla., Jan. 08, 2026 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare and difficult-to-treat diseases, today announced its inclusion in Forbes' esteemed list of America's Most Successful Small-Cap Companies for the year 2026. Catalyst has ranked an impressive 11 out of 100 companies on the list.
Catalyst Pharmaceuticals to Participate in Upcoming Investor Conferences
CPRXCORAL GABLES, Fla., Aug. 28, 2025 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare and difficult-to-treat diseases, today announced that Richard J. Daly, President and CEO of Catalyst, along with other members of Catalyst's management team, will participate in the upcoming investor conferences detailed below.
UPDATED- Catalyst Pharmaceuticals Announces Settlement of FIRDAPSE® (amifampridine) Patent Litigation with Lupin Pharmaceuticals
CPRXAs Part of the Settlement, Lupin Receives a License to Market Generic FIRDAPSE Beginning in February 2035
As Part of the Settlement, Lupin Receives a License to Market Generic FIRDAPSE Beginning in February 2035
Catalyst Pharmaceuticals Reports Record Second Quarter and First Half 2025 Financial Results; Provides Business Update
CPRXAchieved Record Q2 2025 Total Revenues of $146.6 Million, an Increase of 19.4% YoY, Marking Another Quarter of Consecutive Growth
Catalyst Pharmaceuticals Affirms FY2025 Sales Guidance of $545.00M-$565.00M vs $557.24M Est
CPRXCatalyst Pharmaceuticals Q1 Adj. EPS $0.68 Beats $0.53 Estimate, Sales $141.42M Beat $130.86M Estimate
CPRXCatalyst Pharmaceuticals Announces Health Canada Acceptance Of AGAMREE New Drug Submission With Priority Review For Sub-Licensee Kye Pharmaceuticals
CPRXBaird Maintains Outperform on Catalyst Pharmaceuticals, Raises Price Target to $32
CPRXHC Wainwright & Co. Reiterates Buy on Catalyst Pharmaceuticals, Maintains $35 Price Target
CPRXCatalyst Pharmaceuticals Stock: A Deep Dive Into Analyst Perspectives (4 Ratings)
CPRXStephens & Co. Reiterates Overweight on Catalyst Pharmaceuticals, Maintains $33 Price Target
CPRXCatalyst Pharmaceuticals Q4 2024 Adj EPS $0.70 Beats $0.34 Estimate, Sales $141.81M Beat $134.20M Estimate
CPRXHC Wainwright & Co. Maintains Buy on Catalyst Pharmaceuticals, Raises Price Target to $35
CPRXB of A Securities Reiterates Buy on Catalyst Pharmaceuticals, Maintains $30 Price Target
CPRXCatalyst Pharmaceuticals Settles Patent Litigation Case With Teva Pharmaceutical
CPRXCatalyst Pharmaceuticals settles patent litigation with Teva, delaying generic Firdapse launch until 2035. Legal actions against other defendants remain ongoing.
Stephens & Co. Initiates Coverage On Catalyst Pharmaceuticals with Overweight Rating, Announces Price Target of $35
CPRXCatalyst Pharmaceuticals Sees FY24 Revenue $475M-$485M Vs $473.67 Est.
CPRXCatalyst Pharmaceuticals Q3 Adj $0.57 Beats $0.30 Estimate, Sales $126.42M Beat $123.42M Estimate
CPRXA Peek at Catalyst Pharmaceuticals's Future Earnings
CPRXWhy Catalyst Pharmaceuticals Shares Are Popping Off
CPRXCatalyst Pharmaceuticals Inc. (NASDAQ: CPRX) shares are trading higher by 6.40% to $16.12 Tuesday after it was announced the company will join the S&P SmallCap 600.
S&P Dow Jones Indices Says Catalyst Pharmaceuticals To Replace Mantech International Corp. In S&P Smallcap 600 Effective Prior To Market Open On Sept 15
CPRX